Test Your Understanding Quiz 4

Prev
 1 / 17 
Next
Prev
 1 / 17 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • Distinguish therapies that target complement activation from those that target the underlying B-cell clone
  • Select treatment strategies based on the dominant mechanism of disease activity
  • Recognize the strengths and limitations of different therapeutic approaches in CAD
  • Identify clinical scenarios in which complement inhibition, clone-directed therapy, or both may be appropriate

A patient with CAD develops worsening anemia with hemoglobin 7.2 g/dL and laboratory evidence of active hemolysis.

Which treatment strategy most directly targets the mechanism responsible for the anemia?

a
Rituximab therapy
Rituximab targets the B-cell clone producing IgM antibodies but does not immediately stop complement-mediated hemolysis.
b
Complement inhibition therapy
Complement inhibitors such as sutimlimab block activation of the classical complement pathway (C1s), rapidly reducing RBC destruction.
c
Thermal protection measures
Thermal protection helps prevent cold-triggered agglutination but does not directly treat hemolysis.
d
Iron supplementation
Iron supplementation does not address immune-mediated RBC destruction.

Which statement best describes the therapeutic goal of clone-directed therapy in primary CAD?

a
Prevent complement activation on RBCs
Preventing complement activation is the goal of complement inhibitors.
b
Eliminate or suppress the B-cell clone producing pathogenic IgM antibodies
Clone-directed therapy targets the underlying IgM-producing B-cell clone, often using rituximab-based regimens.
c
Increase erythropoiesis
Increasing erythropoiesis does not address the immune mechanism of CAD.
d
Reduce RBC agglutination in peripheral vessels
Agglutination results from antibody binding rather than RBC production.

Which characteristic best distinguishes complement inhibition therapy from clone-directed therapy?

a
Complement inhibitors eliminate the pathogenic B-cell clone
Complement inhibitors do not eliminate the B-cell clone.
b
Complement inhibitors rapidly reduce hemolysis without eliminating antibody production
Complement inhibitors interrupt complement activation and therefore reduce hemolysis within days, but they do not reduce IgM antibody production.
c
Clone-directed therapy works immediately to stop hemolysis
Clone-directed therapy may require weeks to months before antibody levels fall.
d
Clone-directed therapy prevents RBC agglutination
Clone-directed therapy does not directly prevent RBC agglutination.

Which clinical situation most strongly favors complement inhibition therapy rather than clone-directed therapy?

a
Severe hemolytic anemia requiring rapid control
Complement inhibitors can rapidly control hemolysis and are appropriate when immediate improvement in hemoglobin is required.
b
Mild seasonal acrocyanosis without anemia
Mild circulatory symptoms are usually managed with supportive measures.
c
Incidental cold agglutinins without hemolysis
Incidental cold agglutinins without hemolysis do not require therapy.
d
Stable anemia without symptoms
Stable asymptomatic anemia often does not require treatment.

Which therapy is most likely to produce durable reduction in IgM antibody production?

a
Complement inhibition therapy
Complement inhibition suppresses hemolysis but requires ongoing therapy.
b
Clone-directed B-cell therapy
Clone-directed therapies such as rituximab or bendamustine–rituximab target the pathogenic B-cell clone and may produce durable responses.
c
Thermal protection
Thermal protection reduces symptoms but does not alter antibody production.
d
Blood transfusion
Transfusion temporarily replaces RBCs.

Why does complement inhibition therapy often improve anemia quickly but have limited effect on circulatory symptoms?

a
Complement inhibition increases erythropoiesis
Complement inhibitors do not increase erythropoiesis.
b
Circulatory symptoms result from iron deficiency
Circulatory symptoms are unrelated to iron deficiency.
c
Complement inhibitors increase IgM antibody production
Complement inhibitors do not increase antibody production.
d
Circulatory symptoms are caused by RBC agglutination rather than hemolysis
Circulatory symptoms arise from IgM-mediated RBC agglutination in cooled peripheral vessels, which is not directly affected by complement inhibition.

A patient with CAD has persistent hemolysis despite strict thermal protection.

Which therapeutic strategy most directly addresses the remaining mechanism?

a
Complement inhibition therapy
Complement inhibition blocks complement-mediated RBC destruction responsible for hemolysis.
b
Iron supplementation
Iron supplementation does not address immune hemolysis.
c
Splenectomy
Splenectomy is ineffective because hemolysis occurs primarily in the liver.
d
Erythropoietin therapy
Erythropoietin does not treat immune-mediated hemolysis.

Which statement best describes the relationship between complement inhibition and clone-directed therapy?

a
They target different levels of the disease mechanism
Complement inhibition targets the downstream effector pathway, while clone-directed therapy targets the upstream source of antibody production. In some patients, both approaches may be used sequentially or together.
b
Both eliminate the pathogenic antibody
Complement inhibitors do not eliminate the antibody.
c
Both immediately stop hemolysis
Clone-directed therapy does not act immediately.
d
Both prevent RBC agglutination
Neither therapy directly prevents RBC agglutination.

Which patient scenario most strongly suggests the need for disease-modifying therapy rather than supportive care alone?

a
Mild acrocyanosis with hemoglobin 12 g/dL
Mild symptoms without anemia often require conservative management.
b
Incidental cold agglutinins without hemolysis
Incidental cold agglutinins do not require therapy.
c
Occasional cold sensitivity during winter
Seasonal cold sensitivity alone does not justify therapy.
d
Persistent symptomatic anemia with ongoing hemolysis
Persistent symptomatic hemolysis indicates active disease requiring treatment.

A patient treated with complement inhibition therapy experiences rapid improvement in hemoglobin but continues to have mild acrocyanosis.

Which explanation best accounts for this observation?

a
Complement inhibition does not affect IgM-mediated RBC agglutination
Complement inhibitors reduce hemolysis but do not prevent IgM-mediated agglutination in peripheral vessels. As anemia improves, patients may become more active and notice circulatory symptoms more clearly.
b
Complement inhibitors increase RBC destruction
Complement inhibitors reduce rather than increase hemolysis.
c
Complement inhibitors suppress erythropoiesis
Complement inhibitors do not suppress erythropoiesis.
d
Complement inhibitors eliminate IgM antibodies
Complement inhibitors do not eliminate antibody production.

Sort the following therapies according to their primary target.

C1 inhibition
Rituximab
Complement inhibition
Bendamustine–rituximab
B-cell depletion
Complement-targeted therapies
Clone-directed therapies

Match the treatment strategy with its mechanistic target.

Blood transfusion
Bendamustine–rituximab regimen
Rituximab therapy
Temporary correction of anemia
Deeper and more durable suppression of antibody-producing clone
B-cell depletion with moderate response durability
Correct! Sorry, Incorrect.

Closing Note

Therapy for cold agglutinin disease is guided by mechanism.

Complement inhibition targets the effector pathway responsible for hemolysis.

Clone-directed therapy targets the source of the pathogenic antibody.

In some patients, both levels of the disease process must be addressed sequentially or simultaneously to achieve optimal control.

Prev
 1 / 17 
Next